Amaryl; Chlorpropamide; Dymelor; Glimepiride; Glipizide; Glucotrol; Glyburide; Meglitinides; Micronase; Prandin; Repaglinide; Sulfonylurea Hypoglycemic Serum; Sulfonylureas; Tolazamide; Tolinase; Acetohexamide ; Dymelor; Orinase ; Tolbutamide; Diabinese ; Chlorpropamide; HYPOG; Diabinese; Actoplus Met; Actos; Avandamet; Glibenclamide; Glubrava; Glucophage; Lobeglitazone; Meglitinide; Nateglinide; Novonorm; Orinase; Pioglitazone; Piomet; Politor; PPAR; Rosiglitazone; Starlix; Surepost; Thiazolidinedione; Tolazamide; Tolbutamide; Tolinase; Troglitazone; Hypoglycemic Agents
Back to Test Catalogue
Hypoglycemic Agent Screen, Serum
Test ID: HGCAS
Test
Aliases/Synonyms
Method
Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
Report Includes
Chlorpropamide; Glimepiride; Glipizide; Glyburide; Nateglinide; Pioglitazone; Repaglinide; Rosiglitazone; Tolazamide; Tolbutamide
Specimens
Serum
Clinical Utility
Evaluation of suspected insulinoma characterized by hypoglycemia and increased serum insulin concentration.
Detecting drugs that stimulate insulin secretion.
Drugs detected by this procedure are:
- The first-generation sulfonylureas: chlorpropamide (Diabinese), tolazamide, and tolbutamide (Orinase)
- The second-generation sulfonylureas: glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (Glibenclamide)
- The meglitinides: repaglinide (Prandin) and nateglinide (Starlix)
- The thiazolidinediones: pioglitazone (Actos) and rosiglitazone (Avandia)
This test is not intended for therapeutic drug monitoring but could be used to monitor compliance.
Test Version
17-Nov-2025
Specimen
Specimens
Serum
Collection Containers
Red top (no additive)
Sample Volume
1.5 mL
Minimum Volume
0.5 mL
Patient Preparation
Specimen must be collected during an episode of hypoglycemia.
Stability
| Ambient | 7 days |
|---|---|
| Refrigerated | 28 days |
| Frozen | 28 days |
Rejection Criteria
| Specimen | Gel-separator tubes |
|---|
Test Version
17-Nov-2025
Performance / Interpretation
Method
Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
Turnaround Time
8 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| Chlorpropamide |
|
|||
|
Screening cutoff concentration: 100 ng/mL
|
||||
| Glimepiride |
|
|||
|
Screening cutoff concentration: 20 ng/mL
|
||||
| Glipizide |
|
|||
|
Screening cutoff concentration: 5 ng/mL
|
||||
| Glyburide |
|
|||
|
Screening cutoff concentration: 5 ng/mL
|
||||
| Nateglinide |
|
|||
|
Screening cutoff concentration: 5 ng/mL
|
||||
| Pioglitazone |
|
|||
|
Screening cutoff concentration: 20 ng/mL
|
||||
| Repaglinide |
|
|||
|
Screening cutoff concentration: 5 ng/mL
|
||||
| Rosiglitazone |
|
|||
|
Screening cutoff concentration: 20 ng/mL
|
||||
| Tolazamide |
|
|||
|
Screening cutoff concentration: 50 ng/mL
|
||||
| Tolbutamide |
|
|||
|
Screening cutoff concentration: 20 ng/mL
|
||||
Test Version
17-Nov-2025
Interface / Setup
HL7 Interface Codes
| Order Code | Result Codes | Units |
|---|---|---|
| HGCAS | 62021Tolbutamide | ng/mL |
| 62020Tolazamide | ng/mL | |
| 62025Repaglinide | ng/mL | |
| 64293Pioglitazone | ng/mL | |
| 64292Nateglinide | ng/mL | |
| 62024Glyburide | ng/mL | |
| 62023Glipizide | ng/mL | |
| 62022Glimepiride | ng/mL | |
| 62019Chlorpropamide | ng/mL | |
| 62018Acetohexamide | ng/mL | |
| 64294Rosiglitazone | ng/mL |
Test Version
17-Nov-2025